388 related articles for article (PubMed ID: 16498198)
1. "Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage.
Lee KH; Lukovits T; Friedman JA
Neurocrit Care; 2006; 4(1):68-76. PubMed ID: 16498198
[TBL] [Abstract][Full Text] [Related]
2. Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage.
Muench E; Horn P; Bauhuf C; Roth H; Philipps M; Hermann P; Quintel M; Schmiedek P; Vajkoczy P
Crit Care Med; 2007 Aug; 35(8):1844-51; quiz 1852. PubMed ID: 17581487
[TBL] [Abstract][Full Text] [Related]
3. Which H is the most important in triple-H therapy for cerebral vasospasm?
Treggiari MM; Deem S
Curr Opin Crit Care; 2009 Apr; 15(2):83-6. PubMed ID: 19276798
[TBL] [Abstract][Full Text] [Related]
4. [Protective measures against cerebral ischemia following subarachnoid hemorrhage: Part 1].
Romero Kräuchi O; Verger Bennasar AM
Rev Esp Anestesiol Reanim; 2011 Apr; 58(4):230-5. PubMed ID: 21608279
[TBL] [Abstract][Full Text] [Related]
5. Haemodynamic augmentation in the treatment of vasospasm in aneurysmal subarachnoid hemorrhage.
Gura M; Elmaci I; Cerci A; Sagiroglu E; Coskun KK
Turk Neurosurg; 2012; 22(4):435-40. PubMed ID: 22843460
[TBL] [Abstract][Full Text] [Related]
6. Current practices of triple-H prophylaxis and therapy in patients with subarachnoid hemorrhage.
Meyer R; Deem S; Yanez ND; Souter M; Lam A; Treggiari MM
Neurocrit Care; 2011 Feb; 14(1):24-36. PubMed ID: 20838932
[TBL] [Abstract][Full Text] [Related]
7. Posterior Reversible Encephalopathy Syndrome as an Overlooked Complication of Induced Hypertension for Cerebral Vasospasm: Systematic Review and Illustrative Case.
Muhammad S; Güresir Á; Greschus S; Scorzin J; Vatter H; Güresir E
Stroke; 2016 Feb; 47(2):519-22. PubMed ID: 26628389
[TBL] [Abstract][Full Text] [Related]
8. Cerebral vasospasm after aneurysmal subarachnoid hemorrhage: an overview of pharmacologic management.
Liu-Deryke X; Rhoney DH
Pharmacotherapy; 2006 Feb; 26(2):182-203. PubMed ID: 16466324
[TBL] [Abstract][Full Text] [Related]
9. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage.
Sen J; Belli A; Albon H; Morgan L; Petzold A; Kitchen N
Lancet Neurol; 2003 Oct; 2(10):614-21. PubMed ID: 14505583
[TBL] [Abstract][Full Text] [Related]
10. Triple H therapy after aneurysmal subarachnoid hemorrhage. A review.
Romner B; Reinstrup P
Acta Neurochir Suppl; 2001; 77():237-41. PubMed ID: 11563296
[No Abstract] [Full Text] [Related]
11. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage.
Treggiari MM; Walder B; Suter PM; Romand JA
J Neurosurg; 2003 May; 98(5):978-84. PubMed ID: 12744357
[TBL] [Abstract][Full Text] [Related]
12. Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution ("triple-H" therapy) after subarachnoid hemorrhage.
Origitano TC; Wascher TM; Reichman OH; Anderson DE
Neurosurgery; 1990 Nov; 27(5):729-39; discussion 739-40. PubMed ID: 2259403
[TBL] [Abstract][Full Text] [Related]
13. Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.
Shen J; Huang KY; Zhu Y; Pan JW; Jiang H; Weng YX; Zhan RY
J Neurosurg; 2017 Aug; 127(2):291-301. PubMed ID: 27715439
[TBL] [Abstract][Full Text] [Related]
14. New concepts regarding cerebral vasospasm: glial-centric mechanisms.
Mutch WA
Can J Anaesth; 2010 May; 57(5):479-89. PubMed ID: 20131107
[TBL] [Abstract][Full Text] [Related]
15. Early inhibition of natriuresis suppresses symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Nakagawa I; Hironaka Y; Nishimura F; Takeshima Y; Matsuda R; Yamada S; Motoyama Y; Park YS; Nakase H
Cerebrovasc Dis; 2013; 35(2):131-7. PubMed ID: 23406891
[TBL] [Abstract][Full Text] [Related]
16. Effect of triple-h prophylaxis on global end-diastolic volume and clinical outcomes in patients with aneurysmal subarachnoid hemorrhage.
Tagami T; Kuwamoto K; Watanabe A; Unemoto K; Yokobori S; Matsumoto G; Igarashi Y; Yokota H;
Neurocrit Care; 2014 Dec; 21(3):462-9. PubMed ID: 24865266
[TBL] [Abstract][Full Text] [Related]
17. The present role of "triple-H" therapy in the management of cerebral vasospasm.
Findlay JM
World Neurosurg; 2010; 74(2-3):244-6. PubMed ID: 21492545
[No Abstract] [Full Text] [Related]
18. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review.
Dankbaar JW; Slooter AJ; Rinkel GJ; Schaaf IC
Crit Care; 2010; 14(1):R23. PubMed ID: 20175912
[TBL] [Abstract][Full Text] [Related]
19. Medically induced hypertension, hypervolaemia and haemodilution for the treatment and prophylaxis of vasospasm following aneurysmal subarachnoid haemorrhage: systematic review.
Loan JJM; Wiggins AN; Brennan PM
Br J Neurosurg; 2018 Apr; 32(2):157-164. PubMed ID: 29338431
[TBL] [Abstract][Full Text] [Related]
20. Cerebral vasospasm after subarachnoid hemorrhage: hypertensive hypervolemic hemodilution (triple-H) therapy according to new systemic hemodynamic parameters.
Krayenbühl N; Hegner T; Yonekawa Y; Keller E
Acta Neurochir Suppl; 2001; 77():247-50. PubMed ID: 11563298
[No Abstract] [Full Text] [Related]
[Next] [New Search]
